We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In an effort to stay ahead of the threat of evolving superbugs, the National Institutes of Health announced it will fund novel antibiotic research to either complement or replace existing drugs. Read More
Drugmakers need to better connect their clinical and R&D operations to cope with the growing cost and complexity of clinical trials amidst declining drug approvals. Read More
Biosimilar developers can expect the FDA to demand costly clinical trials to verify that a biosimilar is effectively identical with a reference product. Read More